Clinical Trials
9 trialsNCT06393335 2024-05-01
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
The Children's Hospital of Zhejiang University School of Medicine
Phase EARLY_PHASE1 Unknown
NCT06277011 2024-02-26
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Anhui Provincial Hospital
Phase EARLY_PHASE1 Unknown
NCT04696705 2021-01-06
Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Unknown
NCT04638270 2020-11-20
Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT03790891 2020-03-13
Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy
Timmune Biotech Inc.
Phase EARLY_PHASE1 Unknown
NCT04226989 2020-02-21
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy
Zhejiang University
Phase EARLY_PHASE1 Unknown
NCT04169932 2019-11-20
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
Shanghai Longyao Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04028440 2019-09-26
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Unknown
NCT03910842 2019-09-06
Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy
Timmune Biotech Inc.
Phase EARLY_PHASE1 Unknown